Trevor Hallam
2021 - SUTRO BIOPHARMA
In 2021, Trevor Hallam earned a total compensation of $3.4M as Chief Scientific Officer at SUTRO BIOPHARMA, a 176% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $262,500 |
|---|---|
| Option Awards | $1,182,600 |
| Salary | $488,333 |
| Stock Awards | $1,355,650 |
| Other | $132,000 |
| Total | $3,421,083 |
Hallam received $1.4M in stock awards, accounting for 40% of the total pay in 2021.
Hallam also received $262.5K in non-equity incentive plan, $1.2M in option awards, $488.3K in salary and $132K in other compensation.
Rankings
In 2021, Trevor Hallam's compensation ranked 3,917th out of 12,415 executives tracked by ExecPay. In other words, Hallam earned more than 68.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,917 out of 12,415 | 68th |
Division Manufacturing | 1,604 out of 5,505 | 71st |
Major group Chemicals And Allied Products | 659 out of 2,375 | 72nd |
Industry group Drugs | 585 out of 2,096 | 72nd |
Industry Biological Products, Except Diagnostic Substances | 156 out of 449 | 65th |
Source: SEC filing on April 22, 2022.
Hallam's colleagues
We found four more compensation records of executives who worked with Trevor Hallam at SUTRO BIOPHARMA in 2021.
News
SUTRO BIOPHARMA CEO William Newell's 2021 pay jumps 161% to $5.6M
April 22, 2022
SUTRO BIOPHARMA CEO William Newell's 2020 pay falls 44% to $2.2M
April 29, 2021
SUTRO BIOPHARMA CEO William Newell's 2019 pay falls 56% to $3.8M
April 24, 2020
SUTRO BIOPHARMA CEO William Newell's 2018 pay jumps 1,136% to $8.7M
April 25, 2019